BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 28636142)

  • 1. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for prostate cancer: False promises or true hope?
    Rekoske BT; McNeel DG
    Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
    Grosser R; Cherkassky L; Chintala N; Adusumilli PS
    Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune resilience in response to cancer therapy.
    Gicobi JK; Barham W; Dong H
    Cancer Immunol Immunother; 2020 Nov; 69(11):2165-2167. PubMed ID: 33011909
    [No Abstract]   [Full Text] [Related]  

  • 6. The current and emerging role of immunotherapy in prostate cancer.
    Madan RA; Gulley JL
    Clin Genitourin Cancer; 2010 Dec; 8(1):10-6. PubMed ID: 21208850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance and new therapies in colorectal cancer.
    Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
    World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in cancer vaccines for immunotherapy of prostate cancer.
    Jin T; Zhou C; Zhao L; Dong X; Zhou F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):148-156. PubMed ID: 36935188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
    Bilusic M; Heery C; Madan RA
    Vaccine; 2011 Sep; 29(38):6485-97. PubMed ID: 21741424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
    Madan RA; Aragon-Ching JB; Gulley JL; Dahut WL
    Expert Rev Vaccines; 2011 Jun; 10(6):743-53. PubMed ID: 21692697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Prostate Cancer: Where We Are Headed.
    Schepisi G; Farolfi A; Conteduca V; Martignano F; De Lisi D; Ravaglia G; Rossi L; Menna C; Bellia SR; Barone D; Gunelli R; De Giorgi U
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29206214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.
    Rigamonti N; Bellone M
    Cancer Immunol Immunother; 2012 Apr; 61(4):453-68. PubMed ID: 22331081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of mismatch repair deficiency in prostate cancer.
    Sedhom R; Antonarakis ES
    Future Oncol; 2019 Jul; 15(20):2395-2411. PubMed ID: 31237441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There a Role for Immunotherapy in Prostate Cancer?
    Rizzo A; Mollica V; Cimadamore A; Santoni M; Scarpelli M; Giunchi F; Cheng L; Lopez-Beltran A; Fiorentino M; Montironi R; Massari F
    Cells; 2020 Sep; 9(9):. PubMed ID: 32911806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
    Gulley JL; Drake CG
    Clin Cancer Res; 2011 Jun; 17(12):3884-91. PubMed ID: 21680544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
    Surolia I; Gulley J; Madan RA
    Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.
    Cabel L; Loir E; Gravis G; Lavaud P; Massard C; Albiges L; Baciarello G; Loriot Y; Fizazi K
    J Immunother Cancer; 2017; 5():31. PubMed ID: 28428880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
    Madan RA; Gulley JL; Kantoff PW
    Cancer J; 2013; 19(1):50-8. PubMed ID: 23337757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of Prostate Cancer: Facts and Hopes.
    Bilusic M; Madan RA; Gulley JL
    Clin Cancer Res; 2017 Nov; 23(22):6764-6770. PubMed ID: 28663235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.